# Perioperative Management of Antithrombotic Therapy: A Study Guide This study guide provides a comprehensive overview of the 2022 American College of Chest Physicians (CHEST) clinical practice guidelines for the perioperative management of patients receiving long-term oral anticoagulant or antiplatelet therapy. The guide focuses on balancing the risk of perioperative thromboembolism against the risk of surgery-related bleeding. --- ## Core Concepts and Risk Assessment The management of antithrombotic therapy is anchored by the assessment of two competing risks: the patient's baseline risk for a thrombotic event and the specific procedure's risk for causing a major bleed. ### 1. Thromboembolic Risk Stratification Patients are categorized into High, Moderate, or Low risk for arterial thromboembolism (ATE) or venous thromboembolism (VTE). | Risk Category | Mechanical Heart Valve | Atrial Fibrillation | Venous Thromboembolism (VTE) | | :--- | :--- | :--- | :--- | | **High** | Mitral valve; Caged ball or tilting-disc valve; Recent (<3 mo) stroke/TIA. | $CHADS_2$ score 5-6; $CHA_2DS_2VASc$ score $\ge$ 7; Rheumatic valvular disease. | Recent (<3 mo) VTE; Severe thrombophilia (e.g., Protein C/S deficiency); Active cancer. | | **Moderate** | Bileaflet AVR with risk factors; Mitral valve without risk factors. | $CHADS_2$ score 3-4; $CHA_2DS_2VASc$ score 5-6. | VTE within 3–12 months; Recurrent VTE; Non-severe thrombophilia. | | **Low** | Bileaflet AVR without risk factors. | $CHADS_2$ score 0-2 (no prior stroke/TIA). | VTE > 12 months ago without other risk factors. | ### 2. Procedural Bleed Risk Bleed risk is determined by the nature of the surgery and the potential consequences of a bleed (e.g., intracranial or spinal surgery). * **High-Bleed-Risk ($\ge$ 2%):** Major surgery with extensive tissue injury, cancer surgery (solid tumor resection), major orthopedic surgery, vascular organs (kidneys, liver, spleen), cardiac, intracranial, or spinal surgery, and any procedure requiring neuraxial anesthesia. * **Low-to-Moderate-Bleed-Risk (0–2%):** Arthroscopy, cutaneous biopsies, laparoscopic cholecystectomy, and GI endoscopy with biopsy. * **Minimal-Bleed-Risk ($\approx$ 0%):** Minor dental procedures, minor dermatologic procedures (e.g., excision of basal cell carcinoma), cataract surgery, and pacemaker/ICD implantation. --- ## Management Categories ### Vitamin K Antagonists (VKA) and Heparin Bridging For most patients requiring VKA (warfarin) interruption: * **Interruption:** Stop warfarin $\ge$ 5 days before surgery to allow the INR to normalize. * **Resumption:** Resume within 24 hours post-surgery (usually the evening of the procedure) at the patient's maintenance dose. * **Heparin Bridging:** Defined as using short-acting anticoagulants (LMWH or UFH) during VKA interruption. * **Recommendation:** Strong recommendation **against** bridging in patients with Atrial Fibrillation. * **Suggestion:** Bridging is suggested only for **High-Risk** patients (e.g., mechanical mitral valves or very high stroke scores). * **Minor Procedures:** VKAs should generally be **continued** for dental, dermatologic, ophthalmologic, and cardiac device procedures. ### Direct Oral Anticoagulants (DOACs) DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) have a rapid onset and offset, typically obviating the need for heparin bridging. | Drug | Low/Mod Bleed Risk (Interruption) | High Bleed Risk (Interruption) | | :--- | :--- | :--- | | **Apixaban, Edoxaban, Rivaroxaban** | 1 day before surgery | 2 days before surgery | | **Dabigatran ($CrCl \ge 50$ mL/min)** | 1 day before surgery | 2 days before surgery | | **Dabigatran ($CrCl < 50$ mL/min)** | 2 days before surgery | 4 days before surgery | **Resumption:** Resume DOACs > 24 hours after low/moderate-risk procedures and 48–72 hours after high-risk procedures. ### Antiplatelet Therapy * **Aspirin (ASA):** Suggested to **continue** ASA in patients undergoing non-cardiac surgery. * **P2Y12 Inhibitors:** Suggested to **interrupt** clopidogrel (5 days), ticagrelor (3–5 days), or prasugrel (7 days) before surgery. * **Coronary Stents:** Dual antiplatelet therapy (DAPT) should be maintained if surgery occurs within 6–12 weeks of stent placement. If surgery is 3–12 months post-stent, the P2Y12 inhibitor may be stopped while continuing ASA. --- ## Short-Answer Practice Questions 1. **Why is heparin bridging strongly recommended against for patients with atrial fibrillation?** * Evidence (specifically the BRIDGE trial) shows that no bridging is noninferior to bridging for preventing ATE, while bridging significantly increases the risk of major bleeding. 2. **What is the specific interruption requirement for a patient on Dabigatran with a Creatinine Clearance ($CrCl$) < 50 mL/min undergoing high-bleed-risk surgery?** * The drug must be stopped for 4 days before the surgery due to its reliance on renal clearance. 3. **For a patient on Warfarin undergoing a pacemaker implantation, what is the recommended management?** * Continue VKA therapy throughout the procedure; this is proven to result in fewer pocket hematomas than interrupting and bridging with heparin. 4. **What is the recommended timing for stopping Warfarin before an elective procedure?** * $\ge$ 5 days. 5. **Under what circumstances should a clinician consider measuring anti-factor Xa levels for a patient on LMWH bridging?** * The guidelines suggest against routine measurement, but it may be considered for high-bleed-risk surgeries (intracranial/spinal) or urgent non-elective situations. 6. **When should P2Y12 inhibitors be resumed after a Coronary Artery Bypass Graft (CABG) surgery?** * Within 24 hours post-surgery. --- ## Essay Prompts for Deeper Exploration 1. **The Evolution of Bridging Therapy:** Discuss how clinical perspectives on heparin bridging have shifted since 2012. Analyze the impact of the BRIDGE and PERIOP-2 trials on current recommendations for mechanical heart valves and atrial fibrillation. 2. **Pharmacokinetic Logic in DOAC Management:** Explain the rationale behind the 1-to-4-day interruption windows for DOACs. How do drug half-lives and renal function dictate these timelines, and why is heparin bridging considered unnecessary for these agents? 3. **The Complexity of Coronary Stents:** Evaluate the challenges of managing antiplatelet therapy in patients with coronary stents. Discuss the trade-offs between stent thrombosis and surgical bleeding when deciding whether to continue DAPT or interrupt one agent. 4. **Standardization vs. Individualization:** While the guidelines provide standardized care paths, they also emphasize "clinical judgment." Discuss specific patient factors (e.g., age, genetic polymorphisms, type of surgery) that might justify overriding the empiric risk stratification tables. --- ## Glossary of Important Terms * **ATE (Arterial Thromboembolism):** Includes stroke and systemic embolism, primary concerns for patients with atrial fibrillation or mechanical valves. * **aPTT (Activated Partial Thromboplastin Time):** A laboratory test used to monitor the anticoagulant effect of unfractionated heparin (UFH). * **CHADS2 / CHA2DS2VASc:** Clinical prediction rules for estimating the risk of stroke in patients with non-valvular atrial fibrillation. * **DOAC (Direct Oral Anticoagulant):** A class of drugs including apixaban, dabigatran, edoxaban, and rivaroxaban. * **GRADE (Grading of Recommendations, Assessment, Development, and Evaluation):** The methodology used to rate the certainty of evidence and the strength of the clinical recommendations. * **Heparin Bridging:** The administration of a short-acting anticoagulant (LMWH or UFH) during the period when a VKA is interrupted and the INR is sub-therapeutic. * **INR (International Normalized Ratio):** A standardized measurement of the blood's tendency to clot, used to monitor VKA therapy. * **LMWH (Low-Molecular-Weight Heparin):** Typically administered as enoxaparin or dalteparin; the most common agent used for bridging. * **Neuraxial Anesthesia:** Spinal or epidural anesthesia; procedures involving this are automatically classified as high-bleed-risk due to the risk of epidural hematoma. * **P2Y12 Inhibitor:** A class of antiplatelet drugs including clopidogrel, prasugrel, and ticagrelor. * **PICO (Patient, Intervention, Comparator, Outcome):** The framework used to develop the specific clinical questions addressed by the guideline. * **VKA (Vitamin K Antagonist):** Anticoagulants that interfere with Vitamin K metabolism, primarily warfarin. * **VTE (Venous Thromboembolism):** Includes deep vein thrombosis (DVT) and pulmonary embolism (PE).